The primary endpoint was a decrease in the incidence of severe oral mucositis in patients receiving 30 mcg/kg velafermin compared to placebo. Secondary endpoints evaluated included duration of oral mucositis, patient self-reported pain score, use of pain medications, the incidence and duration of febrile neutropenia, and use of enteral or parenteral nutrition.
The complete results from CLN-12 will be presented in December at the American Society of Hematology (ASH) 2007 Annual Meeting in Atlanta, GA.
CuraGen will host a conference call today at 8:30 a.m. Eastern Time. Dial-in and webcast information are provided below.
Dial-in and Webcast Information
Date: Thursday, October 11, 2007
Time: 8:30 a.m. EDT
Dial-in: 877-272-5391 (domestic)
Webcast: Access to the live webcast is available at
A replay of the conference call will be available starting at 12:00 p.m. Eastern time on Thursday, October 11, 2007 through Sunday, November 11, 2007 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 20509852. An archive of the webcast will be available for 30 days at http://www.curagen.com.
Upcoming Presentations at the AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, in San Francisco, CA:
Title: Phase II Multicenter Trial of Belinostat (PXD101) i
|SOURCE CuraGen Corporation|
Copyright©2007 PR Newswire.
All rights reserved